FDA wants MRI contrast agent warning

May 23, 2007

The U.S. Food and Drug Administration wants a warning printed on the labels of all gadolinium-based magnetic resonance imaging contrast agents.

The requested boxed warning would state patients with severe kidney insufficiency who receive the chemicals used to enhance the quality of MRI images are at risk of developing a debilitating and a potentially fatal disease known as nephrogenic systemic fibrosis, or NSF.

In addition, the FDA wants the warning to state that patients just before or just after liver transplantation, or those with chronic liver disease, are also at risk.

Gadolinium-based contrast agents are commonly used to improve the visibility of internal structures when patients undergo an MRI. Reports have identified the development of NSF following single and multiple administrations of the gadolinium-based contrast agents.

Copyright 2007 by United Press International

Explore further: Schumacher's doctor sees progress after injury

add to favorites email to friend print save as pdf

Related Stories

The formation and development of desert dunes on Titan

14 minutes ago

Combining climate models and observations of the surface of Titan from the Cassini probe, a team from the AIM Astrophysics Laboratory (CNRS / CEA / Paris Diderot University) , in collaboration with researchers ...

Recommended for you

Schumacher's doctor sees progress after injury

7 hours ago

A French physician who treated Michael Schumacher for nearly six months after the Formula One champion struck his head in a ski accident says he is no longer in a coma and predicted a possible recovery within three years.

New MCAT shifts focus, will include humanities

Oct 20, 2014

(HealthDay)—The Medical College Admission Test (MCAT) has been revised, and the latest changes, including more humanities such as social sciences, are due to be implemented next April, according to a report ...

User comments : 0